These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. O'Hayre M; Salanga CL; Kipps TJ; Messmer D; Dorrestein PC; Handel TM PLoS One; 2010 Jul; 5(7):e11716. PubMed ID: 20661426 [TBL] [Abstract][Full Text] [Related]
3. Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. Cui XY; Tjønnfjord GE; Kanse SM; Dahm AEA; Iversen N; Myklebust CF; Sun L; Jiang ZX; Ueland T; Campbell JJ; Ho M; Sandset PM Sci Rep; 2021 Mar; 11(1):5127. PubMed ID: 33664415 [TBL] [Abstract][Full Text] [Related]
4. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063 [TBL] [Abstract][Full Text] [Related]
5. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Richardson SJ; Matthews C; Catherwood MA; Alexander HD; Carey BS; Farrugia J; Gardiner A; Mould S; Oscier D; Copplestone JA; Prentice AG Blood; 2006 May; 107(9):3584-92. PubMed ID: 16332969 [TBL] [Abstract][Full Text] [Related]
6. BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia. Haerzschel A; Catusse J; Hutterer E; Paunovic M; Zirlik K; Eibel H; Krenn PW; Hartmann TN; Burger M Ann Hematol; 2016 Dec; 95(12):1979-1988. PubMed ID: 27542958 [TBL] [Abstract][Full Text] [Related]
7. JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia. Montresor A; Toffali L; Mirenda M; Rigo A; Vinante F; Laudanna C Oncotarget; 2015 Oct; 6(33):34245-57. PubMed ID: 26413812 [TBL] [Abstract][Full Text] [Related]
8. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192 [TBL] [Abstract][Full Text] [Related]
9. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Kashyap MK; Kumar D; Jones H; Amaya-Chanaga CI; Choi MY; Melo-Cardenas J; Ale-Ali A; Kuhne MR; Sabbatini P; Cohen LJ; Shelat SG; Rassenti LZ; Kipps TJ; Cardarelli PM; Castro JE Oncotarget; 2016 Jan; 7(3):2809-22. PubMed ID: 26646452 [TBL] [Abstract][Full Text] [Related]
10. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Pavlasova G; Borsky M; Seda V; Cerna K; Osickova J; Doubek M; Mayer J; Calogero R; Trbusek M; Pospisilova S; Davids MS; Kipps TJ; Brown JR; Mraz M Blood; 2016 Sep; 128(12):1609-13. PubMed ID: 27480113 [TBL] [Abstract][Full Text] [Related]
11. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia. Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224 [TBL] [Abstract][Full Text] [Related]
12. Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy. Han TT; Fan L; Li JY; Xu W Cancer Biol Ther; 2014 Jan; 15(1):3-9. PubMed ID: 24149438 [TBL] [Abstract][Full Text] [Related]
13. The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands. Tissino E; Gaglio A; Nicolò A; Pozzo F; Bittolo T; Rossi FM; Bomben R; Nanni P; Cattarossi I; Zaina E; Zimbo AM; Ianna G; Capasso G; Forestieri G; Moia R; Datta M; Härzschel A; Olivieri J; D'Arena G; Laurenti L; Zaja F; Chiarenza A; Palumbo GA; Martino EA; Gentile M; Rossi D; Gaidano G; Del Poeta G; Laureana R; Del Principe MI; Maity PC; Jumaa H; Hartmann TN; Zucchetto A; Gattei V Leukemia; 2024 Oct; 38(10):2127-2140. PubMed ID: 39143370 [TBL] [Abstract][Full Text] [Related]
14. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Hoellenriegel J; Zboralski D; Maasch C; Rosin NY; Wierda WG; Keating MJ; Kruschinski A; Burger JA Blood; 2014 Feb; 123(7):1032-9. PubMed ID: 24277076 [TBL] [Abstract][Full Text] [Related]
15. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1). Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821 [TBL] [Abstract][Full Text] [Related]
16. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. López-Giral S; Quintana NE; Cabrerizo M; Alfonso-Pérez M; Sala-Valdés M; De Soria VG; Fernández-Rañada JM; Fernández-Ruiz E; Muñoz C J Leukoc Biol; 2004 Aug; 76(2):462-71. PubMed ID: 15155773 [TBL] [Abstract][Full Text] [Related]
18. In contrast to high CD49d, low CXCR4 expression indicates the dependency of chronic lymphocytic leukemia (CLL) cells on the microenvironment. Kriston C; Plander M; Márk Á; Sebestyén A; Bugyik E; Matolcsy A; Barna G Ann Hematol; 2018 Nov; 97(11):2145-2152. PubMed ID: 29955944 [TBL] [Abstract][Full Text] [Related]
19. Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia. Butrym A; Gebura K; Iwaszko M; Kuliczkowski K; Bogunia-Kubik K; Mazur G HLA; 2016 Jun; 87(6):432-8. PubMed ID: 27173875 [TBL] [Abstract][Full Text] [Related]
20. CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Barretina J; Juncà J; Llano A; Gutiérrez A; Flores A; Blanco J; Clotet B; Esté JA Ann Hematol; 2003 Aug; 82(8):500-505. PubMed ID: 12783211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]